Rimkus D S, Ashburn W L
Nuclear Medicine Division, University of California, San Diego.
Clin Nucl Med. 1990 Apr;15(4):222-6. doi: 10.1097/00003072-199004000-00002.
A new Tc-99m labeled carbon particle aerosol ("Technegas") has been developed for lung ventilation scanning. This is the first reported clinical study of this agent in the United States. A total of 23 subjects were studied. Thirteen had comparative Xe-133 studies, and in seven patients pulmonary angiograms were available. The Technegas study agreed closely with the Xe-133 results in 10 out of 13 patients, while the pulmonary angiogram confirmed the Technegas and perfusion scan findings in seven out of seven cases. The Technegas scan was easily performed and well tolerated by all patients. If further clinical trials confirm these preliminary findings, Technegas may become the preferred agent for lung ventilation scanning.
一种新的锝-99m标记的碳颗粒气雾剂（“技术气体”）已被开发用于肺部通气扫描。这是该制剂在美国首次报道的临床研究。共对23名受试者进行了研究。其中13人进行了氙-133对比研究，7名患者有肺血管造影资料。在接受技术气体研究的13名患者中，有10名的结果与氙-133研究结果高度一致，而在7例病例中，肺血管造影证实了技术气体和灌注扫描结果。技术气体扫描操作简便，所有患者耐受性良好。如果进一步的临床试验证实这些初步结果，技术气体可能会成为肺部通气扫描的首选制剂。
